| Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT03334409) | Academic and Community Cancer Research United | 2018-02-16 |
| Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer (NCT03050060) | University of Washington | 2017-06-09 |
| A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients (NCT02599779) | Sunnybrook Health Sciences Centre | 2016-12-01 |
| Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic (NCT02721732) | M.D. Anderson Cancer Center | 2016-08-15 |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed (NCT02761057) | National Cancer Institute (NCI) | 2016-07-25 |
| Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery (NCT02595918) | National Cancer Institute (NCI) | 2016-05-19 |
| Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer (NCT02626130) | M.D. Anderson Cancer Center | 2016-03-30 |
| Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery (NCT02210117) | M.D. Anderson Cancer Center | 2014-11-25 |
| Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer (NCT01835158) | National Cancer Institute (NCI) | 2013-07-08 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery (NCT01575548) | National Cancer Institute (NCI) | 2012-08-08 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer (NCT01664182) | National Cancer Institute (NCI) | 2012-08-01 |
| Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer (NCT01480154) | National Cancer Institute (NCI) | 2011-11-23 |
| Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy (NCT01198158) | National Cancer Institute (NCI) | 2010-09-15 |
| Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (NCT01038778) | National Cancer Institute (NCI) | 2009-10-29 |
| Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer (NCT00378703) | National Cancer Institute (NCI) | 2007-09-14 |
| Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer (NCT00121251) | National Cancer Institute (NCI) | 2005-06-03 |